19 min
Boosting the Power of Dendritic Cancer Vaccines The Bio Report
-
- Life Sciences
Jay Hartenbach, chief operating officer of Diakonos Oncology, discusses the company’s dendritic cell cancer vaccine technology, how it works, and why its lead indication is an aggressive form of brain cancer.
Jay Hartenbach, chief operating officer of Diakonos Oncology, discusses the company’s dendritic cell cancer vaccine technology, how it works, and why its lead indication is an aggressive form of brain cancer.
19 min